Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Hopes For Speedy U.S. Launch Of Revo MRI-Friendly Pacer

This article was originally published in The Gray Sheet

Executive Summary

Medtronic is hoping to receive FDA approval of its Revo MRI SureScan MRI-safe pacemaker and launch it in the U.S. within six months now that the device has received a unanimous approval recommendation from an FDA advisory panel
Advertisement

Related Content

CMS Accepts Medtronic’s Request To Reconsider MRI/Pacemaker Policy
CMS Accepts Medtronic’s Request To Reconsider MRI/Pacemaker Policy
Medtronic Revo MRI Pacer Approved, But Still Faces Reimbursement Hurdle
Medtronic Revo MRI Pacer Approved, But Still Faces Reimbursement Hurdle
Medtronic, St. Jude Ask CMS To Ease Restrictions On MRI-Cardio Trials
Medtronic Q1 Revenues Fall 4% On Decreased Hospital Utilization
CMS In Brief
CMS Revisits Coverage Policy For MRI In Patients With Cardiac Implants
Medtronic's Resolute Efficacy On Par With Abbott's Xience In One-Year Study
FDA panel endorses Medtronic Revo MRI pacemaker

Topics

Advertisement
UsernamePublicRestriction

Register

MT028676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel